Department of Gynecologic Surgery and Oncology, Carmel Medical Center, Haifa, Israel.
J Chemother. 2021 Dec;33(8):528-538. doi: 10.1080/1120009X.2021.1899442. Epub 2021 Mar 26.
Since the outbreak of coronavirus disease 2019 (COVID-19), malignancy was shown to be prevalent in COVID-19 patients. This systematic review's searches were conducted in MEDLINE(R), Embase, Web of Science, and Scopos. Considered for inclusion were all reports on outcomes of cancer patients diagnosed with COVID-19. A total of 1099 references were identified through database searching and manual search. Finally, 17 references comprising 88 cancer patients, diagnosed with COVID-19, were included. Prevalence of cancer patients with COVID-19 was shown to range from 0.9% to 3%. The evidence suggested a severe clinical course of 50.6% in COVID-19 diagnosed cancer patients and a mortality rate of 34.5%. Subgroup analysis according to recent anti-cancer treatment showed a similar pattern, with the most concerning results in patients receiving recent immunotherapy/immunosuppressive treatment. COVID-19 morbidity and mortality among cancer patients should be reduced by consideration of testing asymptomatic COVID-19 cancer patients, reduction of hospital visits, and consideration of anti-cancer treatment.
自 2019 年冠状病毒病（COVID-19）爆发以来，癌症在 COVID-19 患者中普遍存在。本系统评价的检索在 MEDLINE（R）、Embase、Web of Science 和 Scopus 中进行。纳入的所有报告均为诊断患有 COVID-19 的癌症患者的结局报告。通过数据库检索和手动检索共确定了 1099 篇参考文献。最终纳入了 17 篇参考文献，共包含 88 例诊断为 COVID-19 的癌症患者。癌症患者中 COVID-19 的患病率范围为 0.9%至 3%。证据表明，COVID-19 确诊癌症患者的临床病程严重程度为 50.6%，死亡率为 34.5%。根据最近的抗癌治疗进行的亚组分析显示出类似的模式，在接受最近的免疫治疗/免疫抑制治疗的患者中结果最令人担忧。通过考虑对无症状 COVID-19 癌症患者进行检测、减少医院就诊次数以及考虑抗癌治疗，可以降低癌症患者的 COVID-19 发病率和死亡率。
